BRUSSELS (Reuters) - Belgian pharma group UCB said on Monday that U.S. health authorities had approved epilepsy drug Keppra XR and that it would go on sale just before its mother drug loses patent ...

UCB today announced findings from new studies of the once-daily antiepileptic drug (AED) Keppra XR™ (levetiracetam) extended-release tablets comparing tolerability vs. levetiracetam immediate release ...

MORRISTOWN, N.J., Sept. 15, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has received FDA approval of Levetiracetam Extended-Release Tablets, ...

NORTH WALES, Pa. Teva Pharmaceuticals has launched levetiracetam tablets, the United States subsidiary of the world's largest generic drug maker announced Thursday. The tablets are available in 250 mg ...

Sept. 16 -- MONDAY, Sept. 15 (HealthDay News) -- The U.S. Food and Drug Administration has approved an extended release form of Keppra (levetiracetam) as an add-on treatment for people with epileptic ...

MASON, Ohio, July 22, 2025 /PRNewswire/ -- Aprecia, the global leader in 3DP (three-dimensional print) technology for commercial-scale pharmaceutical manufacturing, today announced that the U.S. Food ...

The total combined sales for Levetiracetam extended-release tablets, 500mg and 750mg, in the U.S. for the 12 months ending May 31, 2012, were approximately $124.8 million according to IMS Health.

LOS ANGELES, Oct 4 (Reuters) - Pharmaceutical drug maker Mylan Inc said on Thursday it struck an agreement to settle pending litigation with UCB Societe Anonyme and UCB Pharma Inc over Mylan's generic ...